Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam: Prolonged vs. regular infusion

Chinese Critical Care Medicine

Volumn 25, Issue 8, 2013, Pages 479-483

  Lü, Yang ^a   Yan, Zhao ^b   Wang, Dong Hao ^b   Dong, Wei Lin ^b   Yang, Yang ^b   Xia, Rui ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Gram negative bacteria; Hospital acquired pneumonia; Minimum inhibitory concentration; Piperacillin tazobactam; Prolonged infusion time

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN;

ANTIBIOTIC THERAPY; APACHE; ARTICLE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE UNIT; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; PROCESS OPTIMIZATION; RECURRENCE RISK; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; AGED; BACTERIAL PNEUMONIA; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS INFECTION; DRUG ADMINISTRATION; FEMALE; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES;

EID: 84928256542     PISSN: 10030603     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.2095-4352.2013.08.008     Document Type: Article

References (12)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med,2005,171:388-416.
2. Owens RC Jr,Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm, 2009, 66: S23-30.
3. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics - pharmacodynamics of antimicrobial therapy:it's not just for mice anymore. Clin Infect Dis, 2007,44:79-86.
4. Kim A, Sutherland CA, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?. Pharmacotherapy, 2007,27: 1490-1497.
5. Shea KM, Cheatham SC, Smith DW, et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother, 2009, 43 : 1747-1754.
6. Arnold A,Brouse SD,Pitcher WD, et al. Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind. J Intensive Care Med, 2010,25:259-270.
7. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis, 1998, 27: 33-39.
8. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis, 2003, 36: S42-50.
9. Tamma PD,Putcha N,Suh YD,et al. Does prolonged |3- lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis, 2011,11:181.
10. Gonçalves - Pereira J,Oliveira BS,Janeiro S,et al. Continuous infusion of piperacillin/tazobactam in septic critically ill patients- a multicenter propensity matched analysis. PLoS One,2012,7: e49845.
11. Li C, Kuti JL, Nightingale CH,et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother, 2005,56:388-395.
12. Duszynska W,Taccone FS,Switala M,et al. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia:a pilot study on efficacy and costs. Int J Antimicrob Agents,2012,39:153-158.